The burden cost of adverse drug reaction related to admission at Chaophrayayommarat hospital

Abstract

Background: Adverse Drug Reaction-related Hospital Admissions (ADRA) represent a significant impact on clinical problem and healthcare expenditure. This study aimed to determine the clinical manifestations, prevalence and cost burden from ADRA in the context of Chaophrayayommarat hospital, regional hospital level, Thailand. Methods: An observational study of adult patients who unplanned hospital admissions to Chaophrayayommarat hospital caused by adverse drug reactions (ADRs) during May 2024 – March 2025. The prevalence of ADRs, their economic burden from the hospital perspective, severity, and preventability were assessed using standard criteria. Results: Out of 23,247 hospital admissions, 217 ADRA have been identified. The incidence of ADRA was 0.93% (95% CI 0.81-1.06). Antimicrobial agents related ADRs, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Anti-diabetic were the commonest ADRs seen accounting for 27.18, 13.36, and 14.28 events respectively out of the 217 events. Out of 217 events, 143 (65.89%) were identified as the potential preventability of ADRA. The total cost for 217 patients with ADRA admitted to Chaophrayayommarat hospitals was estimated at 1,555,206 Bath. The mean total cost per patient with ADRA was estimated at 7,167 ± 4193 Bath. Conclusion: In addition to the increase in the number of expensive drugs, the ageing population and polypharmacy, the economic impact of ADRA weighs on healthcare spending. It should be emphasized that in most ADRA, medications were contributory reason of hospital admissions and that benefits and risks have to be carefully balanced.